摘要
目的探讨疏肝消脂方治疗酒精性脂肪肝的有效性和安全性。方法将64例符合诊断标准的患者随机分为两组,各32例。治疗组应用疏肝消脂方,随证加减。对照组给予易善复治疗。比较两组的临床疗效、肝功能、血脂的变化情况。观测两组治疗前后血常规、肾功能、心电图等实验室指标及不良反应,评价其安全性。结果治疗组总有效率87.5%明显高于对照组的71.9%,差异具有统计学意义(P<0.05)。两组患者经治疗后AST、ALT、GGT等肝功能指标均较治疗前下降(P<0.05),且治疗组下降程度较对照组明显(P<0.05)。与治疗前比较,两组患者治疗后TC,TG,LDL-C均明显降低(P<0.05),HDL-C明显升高(P<0.05),且治疗后治疗组TC,TG改善程度优于对照组(P<0.05),而治疗组HDL-C、LDL-C改善程度与对照组相比,差异无统计学意义(P>0.05)。两组治疗前后血常规、肾功能、心电图比较,差异无统计学意义(P>0.05);两组患者在治疗期间均未出现不良反应。结论疏肝消脂方治疗酒精性脂肪肝有较好的疗效,它能明显改善肝功能ALT、AST、GGT;调节血脂TC、TG;且未发现不良反应,安全性较好。
OBJECTIVE To evaluate the effectiveness and safety of the Shuganxiaozhi tea on alcoholic fatty liver.METHODS A total of 64 patients were randomly divided into two groups,with 32 cases in each group.The treatment was given the Shuganxiaozhi tea,while the control was given Yishanfu capsules.The clinical efficacy,liver function and blood lipid in the two groups were observed and compared.In addition,blood routine,kidney function,electrocardiogram and other laboratory indicators,and adverse reactions were evaluated and comapred.RESULTS The total efficacy in the treatment group(87.5%)was higher than that in the control group(71.9%),with statistically significant difference(P<0.05).After treatment,the liver function(AST,ALT and GGT)in both groups decreased compared with that before treatment(P<0.05),and the decrease in the treatment was more significant than that in the control group(P<0.05).Compared with before treatment,TC,TG and LDL-C in both groups were significantly decreased after treatment(P<0.05),while HDL-C was increased(P<0.05).Moreover,the improvement of TC and TG in the treatment group was more significant than that in the control group,with no significant difference on the effects of HDL-C and LDL-C between the two groups(P>0.05).There was no significant difference in blood routine,renal function and electrocardiogram between the two groups before and after treatment(P>0.05).No adverse reactions occurred during the treatment in both groups.CONCLUSION The Shuganxiaozhi tea was effective in the treatent of alcoholic fatty liver,with good safety.
作者
伍月红
冯崇廉
刘丽莹
幸宇坚
WU Yuehong;FENG Chonglian;LIU Liying;XING Yujian(Department of Pharmacy,The Third Affiliated,Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510150,China)
出处
《今日药学》
CAS
2020年第1期47-50,共4页
Pharmacy Today
基金
广东省中医药局科研项目(20172107)。
